within Pharmacolibrary.Drugs.ATC.B;

model B02BX07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.21,
    Cl             = 3.16 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 3 / 1000000,
    adminCount     = 1,
    Vd             = 0.105,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004633333333333334,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Lusutrombopag is a small-molecule thrombopoietin (TPO) receptor agonist used to treat thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. It is orally administered and stimulates platelet production by activating the TPO receptor. Lusutrombopag is approved in several countries for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for adults with chronic liver disease, after oral administration of 3 mg once daily, under fasting and fed conditions.</p><h4>References</h4><ol><li><p>Wang, B, et al., &amp; Hu, L (2020). Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, in Rats by UPLC-MS/MS. <i>International journal of analytical chemistry</i> 2020 7290470–None. DOI:<a href=&quot;https://doi.org/10.1155/2020/7290470&quot;>10.1155/2020/7290470</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32550846/&quot;>https://pubmed.ncbi.nlm.nih.gov/32550846</a></p></li><li><p>Katsube, T, et al., &amp; Kano, T (2019). Effects of Food and Calcium Carbonate on the Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist. <i>Clinical therapeutics</i> 41(9) 1747–1754.e2. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2019.06.004&quot;>10.1016/j.clinthera.2019.06.004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31303281/&quot;>https://pubmed.ncbi.nlm.nih.gov/31303281</a></p></li><li><p>Katsube, T, et al., &amp; Wajima, T (2016). Population Pharmacokinetic and Pharmacodynamic Modeling of Lusutrombopag, a Newly Developed Oral Thrombopoietin Receptor Agonist, in Healthy Subjects. <i>Clinical pharmacokinetics</i> 55(11) 1423–1433. DOI:<a href=&quot;https://doi.org/10.1007/s40262-016-0411-6&quot;>10.1007/s40262-016-0411-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27209291/&quot;>https://pubmed.ncbi.nlm.nih.gov/27209291</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B02BX07;
